Affimed Net Profit Margin 2014-2024 | AFMDQ
Affimed net profit margin from 2014 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.
| Affimed Net Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Net Income |
Net Margin |
| 2024-09-30 |
$0.00B |
$-0.08B |
0.00% |
| 2024-06-30 |
$0.00B |
$-0.09B |
-4350.00% |
| 2024-03-31 |
$0.00B |
$-0.10B |
-2550.00% |
| 2023-12-31 |
$0.01B |
$-0.12B |
-1277.78% |
| 2023-09-30 |
$0.02B |
$-0.13B |
-609.52% |
| 2023-06-30 |
$0.03B |
$-0.12B |
-347.06% |
| 2023-03-31 |
$0.04B |
$-0.11B |
-267.50% |
| 2022-12-31 |
$0.04B |
$-0.09B |
-209.09% |
| 2022-09-30 |
$0.04B |
$-0.08B |
-190.91% |
| 2022-06-30 |
$0.04B |
$-0.09B |
-223.08% |
| 2022-03-31 |
$0.04B |
$-0.09B |
-206.98% |
| 2021-12-31 |
$0.05B |
$-0.07B |
-141.67% |
| 2021-09-30 |
$0.05B |
$-0.06B |
-125.53% |
| 2021-06-30 |
$0.05B |
$-0.05B |
-93.88% |
| 2021-03-31 |
$0.04B |
$-0.04B |
-90.00% |
| 2020-12-31 |
$0.03B |
$-0.05B |
-146.88% |
| 2020-09-30 |
$0.03B |
$-0.04B |
-176.00% |
| 2020-06-30 |
$0.02B |
$-0.05B |
-326.67% |
| 2020-03-31 |
$0.02B |
$-0.05B |
-282.35% |
| 2019-12-31 |
$0.02B |
$-0.04B |
-154.17% |
| 2019-09-30 |
$0.05B |
$-0.01B |
-23.40% |
| 2019-06-30 |
$0.05B |
$-0.01B |
-28.89% |
| 2019-03-31 |
$0.04B |
$-0.01B |
-27.50% |
| 2018-12-31 |
$0.03B |
$-0.02B |
-82.14% |
| 2018-09-30 |
$0.00B |
$-0.04B |
-2100.00% |
| 2018-06-30 |
$0.00B |
$-0.04B |
-1266.67% |
| 2018-03-31 |
$0.00B |
$-0.04B |
-925.00% |
| 2017-12-31 |
$0.00B |
$-0.04B |
-1166.67% |
| 2017-09-30 |
$0.00B |
$-0.03B |
-1100.00% |
| 2017-06-30 |
$0.00B |
$-0.03B |
-1133.33% |
| 2017-03-31 |
$0.00B |
$-0.03B |
-850.00% |
| 2016-12-31 |
$0.01B |
$-0.04B |
-583.33% |
| 2016-09-30 |
$0.01B |
$-0.04B |
-514.29% |
| 2016-06-30 |
$0.01B |
$-0.03B |
-471.43% |
| 2016-03-31 |
$0.01B |
$-0.03B |
-428.57% |
| 2015-12-31 |
$0.01B |
$-0.02B |
-287.50% |
| 2015-09-30 |
$0.01B |
$-0.02B |
-366.67% |
| 2015-06-30 |
$0.01B |
$-0.01B |
-71.43% |
| 2015-03-31 |
$0.01B |
$0.02B |
316.67% |
| 2014-12-31 |
$0.00B |
$0.00B |
0.00% |
| 2014-09-30 |
$0.00B |
$-0.01B |
-225.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.009B |
|
Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V., is based in Heidelberg, Germany.
|
